Zealand Pharma A/S announced positive topline results from Part 2 of a Phase 1b multiple ascending dose (MAD) trial, investigating safety, tolerability, and clinical effects of 16 weeks of dosing with petrelintide, a long-acting amylin analog in development for weight management. In Part 2 of the Phase 1b MAD trial, a total of 48 (~80% male) participants with a median age of 49 years and a median baseline BMI of 29 kg/m2, were randomized to receive 16 weekly doses of either petrelintide or placebo (3:1) within three dose cohorts. The company also plans to rapidly progress the clinical development of petrelintide and initiate a Phase 2b clinical trial later in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
869.5 DKK | -0.46% | +34.39% | +132.98% |
26/06 | Zealand Pharma Upsizes Directed Share Offering to $1 Billion Amid Strong Demand | MT |
24/06 | Nordic Shares Rose Monday; ALK-Abello Series B Led Increases | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+132.98% | 779.35Cr | |
+16.70% | 12TCr | |
+19.86% | 12TCr | |
+21.22% | 2.66TCr | |
-23.07% | 1.99TCr | |
-17.47% | 1.63TCr | |
-45.95% | 1.55TCr | |
-18.30% | 1.55TCr | |
+59.67% | 1.48TCr | |
+3.28% | 1.37TCr |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide